| 000 | 01493nam a2200277Ia 4500 | ||
|---|---|---|---|
| 003 | MX-MdCICY | ||
| 005 | 20250625122509.0 | ||
| 040 | _cCICY | ||
| 090 | _aB-6006 | ||
| 245 | 1 | 0 | _aMonoclonal antibody manufacturing in transgenic plants - myths and realities |
| 490 | 0 | _vCurrent Opinion in Biotechnology, 13(6), p.630-635, 2002 | |
| 520 | 3 | _aThe number and types of antibodies expressed in plants has increased steadily since the first reports of this accomplishment in the 1980s, illustrating the versatility of plants as a production system for antibodies. Many recent reviews have detailed the antibody forms that have been derived from plant expression systems. This contribution focuses on the remaining challenges to develop plant-derived therapeutic antibodies into products, and some of the progress that is being made in addressing these challenges. Plants are proving to be a versatile system for the production of antibodies, but some challenges remain | |
| 650 | 1 | 4 | _aMAB |
| 650 | 1 | 4 | _aTRANSGENIC PLANTS |
| 650 | 1 | 4 | _aMOLECULAR FARMING |
| 650 | 1 | 4 | _aGLYCOSYLATION |
| 650 | 1 | 4 | _aCONTAINMENT |
| 650 | 1 | 4 | _aMANUFACTURING CAPACITY |
| 650 | 1 | 4 | _aAVIDIN |
| 700 | 1 | 2 | _aHood, E.E. |
| 700 | 1 | 2 | _aWoodard, S.L. |
| 700 | 1 | 2 | _aHorn, M.E. |
| 856 | 4 | 0 |
_uhttps://drive.google.com/file/d/1i8Z87zpimQOqu74ZjdIAWCEWdArkFgPm/view?usp=drivesdk _zPara ver el documento ingresa a Google con tu cuenta: @cicy.edu.mx |
| 942 |
_2Loc _cREF1 |
||
| 008 | 250602s9999 xx |||||s2 |||| ||und|d | ||
| 999 |
_c40351 _d40351 |
||